论文部分内容阅读
目的探讨125I放射粒子永久性植入治疗激素难治性前列腺癌的临床疗效及其价值。方法直肠B超引导下,经会阴穿刺前列腺125I放射粒子植入治疗激素难治性前列腺癌22例,其中3例合并骨转移。结果 22例手术顺利,平均植入125I放射粒子42粒,平均手术时间60分钟,平均住院时间5天,术后随访8-28月,术后3月前列腺缩小,术后短期IPSS评分上升,但3月后开始好转。完全反应16例,部分反应3例,病情稳定3例,PSA无进展生存率100.0%,未发生严重并发症。结论 125I放射粒子植入治疗激素难治性前列腺癌安全、微创、并发症发生率低,疗效肯定、患者生活质量高。
Objective To investigate the clinical efficacy and value of 125I radioactive particles for permanent implantation of hormone refractory prostate cancer. Methods Under the guidance of rectum B-ultrasound, 22 cases of hormone-refractory prostate cancer were transplanted via transperineal prostatic 125I radioactive particle implantation, of which 3 cases had bone metastasis. Results Twenty-two cases underwent an operation with an average of 42 125I radioactive particles. The average operation time was 60 minutes and the average length of stay was 5 days. The patients were followed up for 8-28 months and the prostate gland was narrowed after 3 months. Short-term IPSS scores increased After March began to improve. Complete response in 16 cases, partial response in 3 cases, 3 cases of stable, PSA progression-free survival rate of 100.0%, no serious complications. CONCLUSION 125I radioactive particle implantation is safe and minimally invasive for hormone-refractory prostate cancer. The incidence of complications is low, and the curative effect is definite. The quality of life of patients is high.